Skip to main content
. 2017 Apr 21;8(28):45323–45334. doi: 10.18632/oncotarget.17335

Figure 7. Schematic model for a novel therapeutic strategy for treating NECC.

Figure 7

Genotoxic agents (i.e., etoposide and cisplatin) could induce DNA damage, while PI3K inhibitor (i.e., BEZ235) blocked PI3K/mTOR pathway and induced caspase-3 activity. With the combination of genotoxic agents and BEZ235, the synergistic effect could further up-regulate the HM-1 apoptosis. The drug combination of genotoxic agents and BEZ235 might be a novel therapeutic option for NECC patients.